Maharashtra FDA cancels Cipla warehouse licences over violations
pre-market1 source ↓written by the desknot a recommendation
Maharashtra's FDA has cancelled licences for Cipla Pharma's Pune warehouse due to violations involving Reactin Plus Tablets. Inspections revealed deficiencies in storage, documentation, and handling of expired medicines. This regulatory action follows the Bombay High Court's directives and may impact Cipla's distribution capabilities in the region.
Not investment advice. For informational purposes only.